22nd Century Group Inc (NASDAQ:XXII)
| 0.97 Delayed Data As of Sep 29 |  +0.0069 / +0.72%Today’s Change | 0.91 Today|||52-Week Range 21.75 | -92.97% Year-to-Date |
Latest XXII News | Press Releases
No recent news for 22nd Century Group Inc.
Today’s Trading
| Previous close | 0.96 |
| Today’s open | 0.98 |
| Day’s range | 0.96 - 0.99 |
| Volume | 3,385 |
| Average volume (3 months) | 1,147,622 |
| Market cap | $22.1M |
Data as of 3:56pm ET, 09/29/2023
Growth & Valuation
| Earnings growth (last year) | -47.49% |
| Earnings growth (this year) | -4,161.29% |
| Earnings growth (next 5 years) | +30.00% |
| Revenue growth (last year) | +100.69% |
| P/E ratio | NM |
| Price/Sales | 2.86 |
| Price/Book | 0.16 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| VBLTVascular Biogenics L... | +0.01 | +6.52% |
| MBOTMicrobot Medical Inc | +0.06 | +4.51% |
| APTOAptose Biosciences I... | +0.02 | +0.72% |
| MDNAMedicenna Therapeuti... | +0.01 | +3.94% |
Data as of 4:00pm ET, 09/29/2023
Financials
| Next reporting date | November 9, 2023 |
| EPS forecast (this quarter) | -$47.59 |
| Annual revenue (last year) | $62.1M |
| Annual profit (last year) | -$59.8M |
| Net profit margin | -96.28% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Buffalo, New York |
Forecasts
